Combining Daratumumab with VRd Improves Outcomes in Patients with Transplant-Ineligible or Transplant-Deferred Newly Diagnosed Multiple Myeloma By Ogkologos - March 3, 2025 851 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CEPHEUS study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Man Who Lost Wife to Breast Cancer Wants to Donate Her... June 5, 2021 Study Shows 4 Drugs Better Than 3 for Women with HER2-Positive... June 21, 2021 EMA Recommends Extension of Indications for Acalabrutinib to Include the Treatment... April 3, 2025 Prognostic Role of ctDNA in Patients with Surgically Resectable Colorectal Cancer January 30, 2023 Load more HOT NEWS Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual TNBC Following Neoadjuvant... Women in science: Cancer research pioneers – part 1 Happy 29th Birthday OncoLink! New Research in Treating Non-Small Cell Lung Cancer: 2022 North America...
